| Name | Title | Contact Details |
|---|
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.
Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.
Unipex Solutions is a Quí©bec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Dendritic NanoTechnologies, Inc. is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.